Sequenom Licenses IP for Maternal Urine Tests

10/30/08

Sequenom (NASDAQ:SQNM), a San Diego-based provider of molecular diagnostics, reports that it has licensed exclusive rights from Monmouth Junction, NJ, diagnostics firm Xenomics (PINK:XNOM) to U.S. and European patents that cover the use of fetal DNA fragments found in a mother’s urine for prenatal diagnostics and research. As Luke discusses in this story, Sequenom is already deep into development of prenatal diagnostics that capture fetal DNA fragments from mothers’ blood samples.

By posting a comment, you agree to our terms and conditions.